Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Incretin-Based Drugs Market Heading Into 2029?

In recent years, the market size for incretin-based drugs has impressively expanded. It’s expected to rise from a worth of $25.89 billion in 2024 to a projected $27.83 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.5%. This significant growth during the historical period can be linked to numerous factors. These include the growing incidence of type 2 diabetes worldwide and the launch of GLP-1 receptor agonists like exenatide and liraglutide. Additionally, the inflow of research and development investments, the approval favorable from regulatory bodies for DPP-4 and GLP-1 drugs, the shift from insulin and sulfonylureas to more modern drug classes, and the emergence of injectable formulations available once a week have all further fueled this surge.

The market for incretin-based drugs is set for significant expansion in the coming years, swelling to a sizable $36.7 billion by 2029 with a compound annual growth rate (CAGR) of 7.2%. This anticipated growth within the predicted period is likely due to a rising inclination towards fixed-dose combination therapies, an amplified emphasis on weight management and diabetes connected to obesity, advancements in personalized medicine and accompaniment diagnostics, growing demand for minimally invasive delivery techniques for drugs, as well as a rising aged population with higher comorbidity complications. Important trends emerging within this period encompass the usage of incretin drugs within obesity management programs, the emergence of dual and triple agonists to boost metabolic results, the incorporation of digital health into incretin treatments for individual monitoring, the dominance of combination treatments over monotherapy for improved diabetes regulation, and a focus on long-lasting weekly injections for the reduction of dosing burden.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Factors Are Pushing The Incretin-Based Drugs Market Forward?

The incretin-based drugs market is anticipated to grow due to the increasing prevalence of type 2 diabetes mellitus. This chronic metabolic disorder, featuring insulin resistance and deficient insulin secretion, escalates levels of glucose in the blood. The occurrence of Type 2 diabetes is commonly linked to poor nutrition and lack of physical activity which causes insulin resistance, thus negatively affecting the body’s ability to regulate blood sugar levels. Incretin-based medications improve this type of diabetes by elevating insulin release post-meal, reducing glucagon production, and therefore, lowering blood sugar. These drugs also slow down stomach emptying and suppress appetite, which aids in glucose management and weight loss. For instance, the National Health Service, a government department in the UK, stated in June 2024 that in 2023, approximately 549,000 more individuals in England were at risk of developing type 2 diabetes. This brought the total number of pre-diabetic individuals to over 3.6 million, which is almost a 20% rise from 2022. Consequently, due to the escalating prevalence of type 2 diabetes mellitus, the incretin-based drugs market is witnessing growth.

Which Segment Held The Largest Share In The Incretin-Based Drugs Market In 2025?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide, Albiglutide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

How Are Key Trends Driving Expansion In The Incretin-Based Drugs Industry?

Key players in the incretin-based drugs market are striving to create a generic version of drugs as a more potent and user-friendly treatment solution for type 2 diabetes. A generic drug contains equivalent active ingredients, strength, dosage form, and administration path as a branded drug, but it is sold under its chemical name without the branding. To illustrate, Hikma Pharmaceuticals PLC, a pharmaceutical company from the UK, introduced the first generic version of Victoza, which is a liraglutide injection of 6 mg/mL, in America in December 2024. The Food and Drug Administration (FDA) gave its approval. It was specified to be used as a supplementary measure to diet and exercise for better glycemic control in adults and children aged 10 or above who have type 2 diabetes. It thus offers a fresh and more economical alternative at a time when GLP-1 medications are in scarce supply.

Which Organizations Are Driving Progress In The Incretin-Based Drugs Industry?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Incretin-Based Drugs Industry?

North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model